MedTrace Logo

Association of Coffee With Periodontal Status

NCT07166276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 318

Last updated 2025-11-21

No results posted yet for this study

Summary

A total of 318 patients applying to Bolu Abant İzzet Baysal University will be included in the study. Based on anamnesis, radiographic examination, and the 2018 classification of periodontal diseases, the participants will be categorized into three groups: periodontal health (n=106), gingivitis (n=106), and periodontitis (n=106). Information regarding participants' coffee consumption habits and their daily coffee intake will be collected. Clinical parameters to be measured will include plaque index, gingival index, bleeding on probing, gingival recession, and clinical attachment level.

The frequency of coffee consumption will be evaluated as daily, 1-2 times per week, 3-4 times per week, once per month, twice per month, and once per year. The amount of coffee consumed at a single occasion (cup, glass, mug, etc.) will also be recorded. In caffeinated coffee consumption, the preference for weak, moderate, or strong coffee, as well as consumption with milk, condensed milk, sugar, honey, or sweeteners will be assessed. For Turkish coffee, the consumption pattern will be categorized as unsweetened, moderately sweetened, or sweetened.

Conditions

  • Periodontal Diseases

Interventions

OTHER

coffee

The type of coffee consumed, the daily amount of coffee, and the frequency of consumption were measured.

Sponsors & Collaborators

  • Tuğba ŞAHİN

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-19
Primary Completion
2025-07-28
Completion
2025-08-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166276 on ClinicalTrials.gov